全文获取类型
收费全文 | 4165篇 |
免费 | 290篇 |
国内免费 | 19篇 |
专业分类
耳鼻咽喉 | 21篇 |
儿科学 | 120篇 |
妇产科学 | 93篇 |
基础医学 | 784篇 |
口腔科学 | 138篇 |
临床医学 | 370篇 |
内科学 | 752篇 |
皮肤病学 | 140篇 |
神经病学 | 609篇 |
特种医学 | 139篇 |
外科学 | 420篇 |
综合类 | 22篇 |
一般理论 | 2篇 |
预防医学 | 223篇 |
眼科学 | 67篇 |
药学 | 311篇 |
中国医学 | 2篇 |
肿瘤学 | 261篇 |
出版年
2024年 | 2篇 |
2023年 | 38篇 |
2022年 | 55篇 |
2021年 | 99篇 |
2020年 | 81篇 |
2019年 | 113篇 |
2018年 | 98篇 |
2017年 | 76篇 |
2016年 | 116篇 |
2015年 | 134篇 |
2014年 | 167篇 |
2013年 | 168篇 |
2012年 | 315篇 |
2011年 | 336篇 |
2010年 | 196篇 |
2009年 | 191篇 |
2008年 | 319篇 |
2007年 | 298篇 |
2006年 | 288篇 |
2005年 | 256篇 |
2004年 | 287篇 |
2003年 | 248篇 |
2002年 | 217篇 |
2001年 | 33篇 |
2000年 | 30篇 |
1999年 | 48篇 |
1998年 | 41篇 |
1997年 | 34篇 |
1996年 | 26篇 |
1995年 | 25篇 |
1994年 | 30篇 |
1993年 | 20篇 |
1992年 | 16篇 |
1991年 | 15篇 |
1990年 | 7篇 |
1989年 | 8篇 |
1988年 | 2篇 |
1986年 | 7篇 |
1985年 | 4篇 |
1984年 | 2篇 |
1983年 | 3篇 |
1982年 | 2篇 |
1977年 | 2篇 |
1976年 | 3篇 |
1972年 | 2篇 |
1970年 | 2篇 |
1968年 | 1篇 |
1960年 | 1篇 |
1947年 | 1篇 |
1946年 | 1篇 |
排序方式: 共有4474条查询结果,搜索用时 15 毫秒
1.
We have shown previously that the plant cannabinoid cannabidiol (CBD) elevates intracellular calcium levels in both cultured hippocampal neurones and glia. Here, we investigated whether the main psychotropic constituent of cannabis, Δ9-tetrahydrocannabinol (THC) alone or in combination with other cannabis constituents can cause similar responses, and whether THC affects the responses induced by CBD. Our experiments were performed with 1 μM pure THC (pTHC), with 1 μM pure CBD (pCBD), with a high-THC, low CBD cannabis extract (eTHC), with a high-CBD, low THC cannabis extract (eCBD), with a mixture of eTHC and eCBD (THC:CBD = 1:1) or with corresponding ‘mock extracts’ that contained only pTHC and pCBD mixed in the same proportion as in eTHC, eCBD or the 1:1 mixture of eTHC and eCBD. 相似文献
2.
Prof. Dr. Alexander Kapp Prof. Dr. Bettina Wedi 《Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete》2006,57(10):854-854
Ohne Zusammenfassung 相似文献
3.
Role of rufinamide in the management of Lennox-Gastaut syndrome (childhood epileptic encephalopathy)
下载免费PDF全文
![点击此处可从《Neuropsychiatric Disease and Treatment》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Rufinamide, a triazole derivative that is structurally distinct from currently marketed antiepileptic drugs (AEDs), is in development for the adjunctive treatment of Lennox-Gastaut syndrome (LGS) in children and adults. Rufinamide is well absorbed after oral administration, demonstrates low protein binding, and is metabolized by enzymatic hydrolysis without involvement of cytochrome P450 enzymes, conferring a low drug interaction potential. In a randomized, double-blind trial involving 138 adult and pediatric patients with LGS, compared with placebo, rufinamide 45 mg/kg/day resulted in significantly superior reductions in drop attacks (median change −42.5% vs +1.4% with placebo) and total seizures (−32.1% vs −11.7% with placebo), accompanied by significantly higher responder rates. These results are comparable with findings reported for other AEDs in randomized, controlled clinical trials in patients with LGS. Rufinamide produced statistically significant seizure reduction which was maintained during long-term therapy and accompanied by good tolerability. The most frequently reported adverse events from a pooled safety database evaluating short- and long-term therapy were headache (22.9% and 29.5%), dizziness (15.5% and 22.5%) and fatigue (13.6% and 17.7%). Rufinamide therefore presents a favorable efficacy and tolerability profile and is a promising candidate for the adjunctive therapy of LGS. 相似文献
4.
Klaus Rauber Kathrin S. Heidinger Bettina Kemkes-Matthes 《Cardiovascular and interventional radiology》1997,20(3):169-173
Purpose To determine the systemic effects of local fibrinolytic therapy with low-dose recombinant tissue-type plasminogen activator
(rt-PA).
Methods Ten patients received intrathrombal infusion of 20 mg rt-PA and heparin for local thrombolysis and had subsequent percutaneous
transluminal angioplasty (PTA). Eight controls underwent PTA and received heparin alone. We measured t-PA, D-Dimer, and fibrinogen
levels before, directly after, and 20, 40, and 60 min and 24 hr after therapy.
Results In the thrombolysis group the t-PA level peaked immediately after infusion and then declined within 1 hr. D-Dimer increased
and remained elevated, whereas in the control group only t-PA levels increased, and only after 24 hr. Fibrinogen remained
within the normal range in both groups. Eight of ten patients in the thrombolysis group and seven of eight with PTA had clinical
improvement after the procedure.
Conclusions The increase in D-Dimer in the rt-PA group indicates a good local fibrinolytic effect. The fact that fibrinogen levels remained
unchanged indicates that there is a lack of systemic fibrinogenolysis. 相似文献
5.
Bettina Seiberlich Nicolas Hunzelmann Axel Roers Manfred Weber Eckhard Schulze-Lohoff 《Medizinische Klinik》2005,108(4):137-142
Namensgebend für das Jo-1-Syndrom sind Autoantikörper gegen das Jo-1-Antigen, die bei diesem Krankheitsbild im Serum der betroffenen Patienten nachgewiesen werden. Der Name Jo-1 leitet sich von dem ersten Patienten (John P.) ab, bei dem diese Antikörper gefunden wurden. Dieser Patient litt an einer Polymyositis und fibrosierenden Alveolitis. Das Jo-1-Antigen ist identisch mit der Histidyl-Transfer-RNA-Synthetase im Zytosol. Das Jo-1-Syndrom gehört zu einer Familie von Autoimmunerkrankungen, die als Anti-Synthetase- Syndrome bezeichnet werden. Diese Syndrome haben gemeinsam, dass jeweils Autoantikörper gegen unterschiedliche Aminosäure-Transfer-RNASynthetasen nachweisbar sind. Klinisch handelt es sich beim Jo-1-Syndrom um eine Sonderform der Poly- bzw. Dermatomyositis von bisher ungeklärter Ätiologie. Neben einer Muskelbeteiligung kommt es charakteristischerweise zu einer interstitiellen Lungenbeteiligung, die auch prognostisch das Krankheitsbild bestimmt. Zusätzlich können klinisch eine Polyarthritis und weitere Symptome bestehen, die dem klinischen Bild anderer Kollagenosen ähneln. Ebenso wie die Polymyositis und Dermatomyositis kann sich das Jo-1-Syndrom in sog. Myositis-Overlap-Syndromen präsentieren. Zu dieser Diagnose führt ein Symptomenkomplex, der die klare Zuordnung zu einer einzelnen Erkrankung nicht möglich macht. Häufig werden in solchen Fällen U1-RNP-Antikörper nachgewiesen. Therapeutisch spricht das Jo-1-Syndrom auf die Gabe von Kortikosteroiden und—falls notwendig—Azathioprin, Methotrexat und Cyclophosphamid an. Eine Kurzbeschreibung von zwei klinischen Fällen stellt das Krankheitsbild anschaulich dar. 相似文献
6.
Markus Donix Bettina Beuthien-Baumann Rüdiger von Kummer Georg Gahn Fatima Thomas Vjera Holthoff 《Journal of clinical neuroscience》2007,14(6):601-603
Waldenstrom's macroglobulinemia (WM) is an uncommon low-grade lymphoma. Cognitive impairment due to central nervous system infiltration by lymphoplasmocytoid cells (Bing-Neel syndrome) has been rarely reported. We describe a 54-year-old man who was referred to a memory disorder clinic with a 9-month history of clinically obvious nonfluent aphasia and WM. He underwent extensive neuropsychological testing, clinical examination and structural and functional brain imaging. The diagnosis of the diffuse form of the Bing-Neel syndrome was supported by abnormal lymphoid cells found in the cerebrospinal fluid. Structural and functional brain imaging revealed impairment of brain areas due to white matter changes and subsequent functional deficits mimicking the neuropsychological syndrome encountered in progressive nonfluent aphasia. The diffuse form of Bing-Neel syndrome and neurological deficits are assumed to be the result of leptomeningeal infiltration by malignant cells and/or neoplastic vascular obstruction. 相似文献
7.
Birgit Herting MD Bettina Beuthien‐Baumann MD Katrin Pöttrich PhD Markus Donix MD Antje Triemer PhD Johannes B. Lampe MD Rüdiger von Kummer MD Karl Herholz MD Heinz Reichmann MD Vjera A. Holthoff MD 《Movement disorders》2007,22(4):490-497
Depressive symptoms are common in patients with neurodegenerative disorders. Imaging studies suggest that a disruption of frontal-subcortical pathways may underlie depression associated with basal ganglia disease. This pilot study tested the hypothesis that frontal dysfunction contributes to depression associated with multiple system atrophy (MSA) and progressive supranuclear palsy (PSP). Depressed patients with MSA (n = 11), PSP (n = 9), and age-matched controls (n = 25) underwent measures of cerebral glucose metabolism applying positron emission tomography with (18)F-fluorodeoxyglucose. Regional metabolism in the patient groups was compared to the normal subjects using the voxel-based statistical parametric mapping. Depressive symptom severity (Hamilton Depression Rating) and degree of locomotor disability (Hoehn & Yahr) were assessed in the patient groups. The association between prefrontal metabolism and the occurrence of depressive symptoms and the degree of locomotor disability was investigated. When compared to controls, MSA patients revealed significant metabolic decreases in bilateral frontal, parietal, and cerebellar cortex and in the left putamen. In PSP patients, significant hypometabolism was demonstrated in bilateral frontal cortex, right thalamus, and midbrain. Depression severity but not the patients' functional condition was significantly associated with dorsolateral prefrontal glucose metabolism in both patient groups. The findings of this pilot study support the hypothesis that depressive symptoms in MSA and PSP are associated with prefrontal dysfunction. 相似文献
8.
Manic episode with psychotic symptoms induced by subthalamic nucleus stimulation in a patient with Parkinson's disease. 总被引:5,自引:0,他引:5
Jan Herzog Julia Reiff Paul Krack Karsten Witt Bettina Schrader Dieter Müller Günther Deuschl 《Movement disorders》2003,18(11):1382-1384
Deep brain stimulation of the subthalamic nucleus (STN-DBS) is an established therapy for Parkinson's disease (PD). A manic episode with psychotic symptoms induced by STN-DBS occurred in a previously psychiatrically healthy patient, focusing on the role of STN-DBS in influencing not only motor but also emotional behaviour. 相似文献
9.
10.
Different proliferative activity of the glandular and myoepithelial lineages in benign proliferative and early malignant breast diseases. 总被引:3,自引:0,他引:3
Agnes Bánkfalvi Andreas Ludwig Bettina De-Hesselle Horst Buerger Igor B Buchwalow Werner Boecker 《Modern pathology》2004,17(9):1051-1061
The aim of the present study was to explore cell biological characteristics of normal breast, benign proliferative breast diseases and noninvasive breast malignancies based on the recently published adult progenitor cell concept from our group. Here, we investigated the proliferative activity of CK5/14(+), CK8/18/19(+) and alpha-smooth muscle actin(+) cellular phenotypes encountered in normal mammary gland, in a series of usual ductal hyperplasias and early malignant breast diseases, such as atypical ductal and lobular hyperplasias, as well as ductal and lobular in situ carcinomas. Immunohistochemical double labeling was performed on frozen sections from diagnostic breast biopsies by using antibodies to basal cytokeratins (CK5/14), glandular cytokeratins (CK8/18/19), smooth muscle actin and the Ki-67 antigen (MIB1). Normal breast tissues and usual ductal hyperplasias were characterized by a heterogeneous cellular composition of the growth fraction. The proliferative cell compartment consisted of CK8/18/19(+) glandular and, in a variable proportion, CK5/14(+) progenitor phenotypes. In contrast, noninvasive breast malignancies were composed of a monotonous proliferation of CK 8/18/19(+) neoplastic glandular cells. These findings indicate a significant role of progenitor cells in the development of benign proliferative breast diseases and lend support to the view that malignant transformation in the human breast usually occurs in a cell committed to the glandular lineage. Our results provide cell kinetic support to the functional progenitor cell hypothesis, and we propose this concept as an operative model for understanding benign proliferative and malignant breast diseases. 相似文献